In cellular models, the two compounds demonstrated anticancer activity at 0.1 mM in cell growth inhibition assays, where the sensitivity of FK866 to NAPRT-expressing ovarian cancer (OVCAR-5 and OVCAR-8) and colorectal cancer (HCT116) cell lines could be restored [89]. The gene discussed is NAPRT; the disease is ovarian carcinoma.